SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SABS Hot Sheet
Price: $3.12 --0%
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
14 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Edward White raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $10.00 (from $1.00) while maintaining a Buy rating.
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $465 at Cantor Fitzgerald
- Dicker Data Ltd (DDR:AU) PT Raised to AUD15.90 at UBS
- Akums Drugs & Pharmaceuticals (AKUMS:IN) PT Raised to INR925 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
